A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

NCT Number	NCT07564414
Lead Sponsor	Novo Nordisk A/S
Conditions	Obesity, Type 2 Diabetes
Enrollment	2,500 participants
Start Date	2026-05-21
Primary Completion	2028-02-23 (estimated)
Study Completion	2028-04-19 (estimated)
Updated on ClinicalTrials.gov	2026-07-08